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Background: Concurrent infection may be found in Pneumocystis jirovecii pneumonia (PJP) of non-acquired
immunodeficiency syndrome (AIDS) patients, however, its impact on immune dysregulation of PJP in non-AIDS
patients remains unknown.
Methods: We measured pro-inflammatory cytokines including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-8,
IL-17, monocyte chemoattractant protein-1 (MCP-1) and anti-inflammatory cytokines including IL-10 and transforming
growth factor (TGF)-β1 and IL-1 receptor antagonist (IL-1RA) and inflammatory markers including high mobility group
box 1, Krebs von den Lungen-6, receptor for advanced glycation end product, advanced glycation end product,
surfactant protein D in bronchoalveolar lavage fluid (BALF) and blood in 47 pure PcP and 18 mixed PJP and other
pulmonary infections (mixed PJP) in non-AIDS immunocompromised patients and explored their clinical relevance.
The burden of Pneumocystis jirovecii in the lung was determined by counting number of clusters of Pneumocystis
jirovecii per slide and the concentration of β-D-glucan in BALF. PJP severity was determined by arterial oxygen
tension/fraction of inspired oxygen concentration ratio, the need of mechanical ventilation and death.
Results: Compared with pure PJP group, mixed PJP group had significantly higher BALF levels of IL-1β, TNF-α and
IL-8 and significantly higher blood levels of IL-8. The BALF ratios of TNF-α/IL-10, IL-8/IL-10, IL-1β/IL-10, TNF-α/TGF-β1,
IL-8/TGF-β1, IL-1β/TGF-β1 and IL-1β/IL-1RA were significantly higher in mixed than in pure PJP patients. There was no
significant difference in clinical features and outcome between pure and mixed PJP groups, including inflammatory
biomarkers and the fungal burden. In pure PJP patients, significantly higher BALF levels of IL-8 and the ratios of
IL-8/IL-10, IL-1β/TGF-β1, MCP-1/TGF-β1, MCP-1/IL1RA and IL-8/TGF-β1 were found in the patients requiring
mechanical ventilation and in non-survivors.
Conclusions: In summary, concurrent pulmonary infection might enhance immune dysregulation of PJP in non-AIDS
immunocompromised patients, but did not affect the outcome as evidenced by morbidity and mortality. Because of
limited number of cases studied, further studies with larger populations are needed to verify these issues.
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Pneumocystis is an opportunistic fungal pathogen that
causes Pneumocystis jirovecii pneumonia (PJP). PJP-related
morbidity and mortality appear to be a major health prob-
lem for patients with acquired immunodeficiency syndrome
(AIDS) and for those with immunosuppression resulted
from chemotherapy, organ transplantation and long-term
treatment with steroid or other immunosuppressants for
a variety of diseases [1]. The clinical features, radiological
findings, response to treatment and outcome of PJP are
reported to be widely different between the patients with or
without AIDS [2,3]. The reasons underlying the differences
in clinical features, radiological findings, treatment response
and outcome of PJP between the patients with and without
AIDS remain to be elucidated.
Some studies suggest that pathology of PJP inflamma-
tory response is the main factor attributed to morbidity
and mortality of PJP patients [4-8], although pathology
itself and underlying disorders resulting in impaired
immune function are also of clinical importance. Our
and previous studies [9,10] indicated that immune dys-
regulation was found in PJP of the patients with AIDS
and non-AIDS, and certain pro-inflammatory cytokine/
anti-inflammatory cytokine ratios in bronchoalveolar
lavage fluid (BALF) were of considerable value in assessing
the severity of PJP and outcome of the patients [10].
Mixed pulmonary infections including PJP and other
pathogens are uncommon in patients with AIDS or
non-AIDS immunocompromised hosts. In this study, we
intended to explore the impact of concomitant pulmonary
infection on immune dysregulation of PJP as evidenced
by the changes in pro-inflammatory cytokines and anti-
inflammatory cytokines and its clinical relevance. Our
study results showed concurrent pulmonary infection
might enhance immune dysregulation of PJP in non-
AIDS immunocompromised patients, but did not affect
the outcome as evidenced by morbidity and mortality.
Methods
Non-AIDS PJP patients
Sixty five consecutive non-AIDS immunocompromised
patients with PJP diagnosed by identification of Pneumo-
cystis jirovecii cysts or trophozoites in Papanicolaou- and
Gomori methenamine silver stained-smears of BALF at
Taipei Veterans General Hospital from November 1987
to September 2012 were included for this study. The
patients were classified into two groups. One group
included patients with pure PJP. The other group
included those with PJP and concomitant pulmonary
infection including cytomegalovirus (CMV) pneumonia
and/or co-infections with other pathogens. Peripheral
blood samples were collected after bronchoalveolar lavage
(BAL) for measurements of cytokines and inflammatory
biomarkers. The institutional Review Board of TaipeiVeterans General Hospital approved the study (No:
201009019IC and No: 96-04-02A), and written informed
consent was obtained from all patients before entering the
study of cytokines and inflammatory biomarkers in BALF
and blood.
Diagnostic criteria
Bacterial pneumonia was diagnosed when a quantitative
bacterial culture from BALF samples grew pathogenic
bacteria >104 colonies/mL. CMV was considered to be
the pathogen if it was demonstrated on BALF cytology
smears or positive result of CMV culture from BALF.
Fungal pneumonia was diagnosed when one of the
following criteria was met: (1) fungi were identified by
microbiologic studies in at least two different lower
respiratory tract secretions including BALF; (2) fungi
were demonstrated by cytology smears of BALF in the
presence of a compatible clinical and chest imaging
findings; (3) fungi were demonstrated by histopatho-
logical examination of lung biopsy specimens; (4) positive
results of blood cultures in the presence of compatible
clinical and chest imaging features. Legionella infection
was considered when single serum indirect fluorescent
antibody titer was ≧1:256.
Oxygenation index
The arterial oxygen tension (PaO2) was analyzed with
ABL III (Radiometer, Copenhagen, Denmark). Oxygen-
ation index (PaO2/FiO2 ratio) was calculated as PaO2
divided by inspired oxygen fraction (FiO2).
BALF and blood samples
The fiberoptic bronchoscope (Model BF20 or P20;
Olympus, Tokyo, Japan) was wedged in the orifice of a
lobar or segmental bronchus of the right middle lobe
or lingular division or other appropriate location. Diag-
nostic BAL was done using three aliquots of a 50-mL
sterile isotonic sodium chloride. Aspirates were pooled
into a siliconized container and kept on ice during
transport. Part of the retrieved BALF was subjected to
Papanicolaou and Riu’s staining routinely. Some slides
were stored for subsequent special staining if clinically
indicated. A 10-mL sample of venous blood was drawn
immediately after BAL. The supernatants of blood and
BALF were frozen and stored at −70°C until analyzed.
BALF cell analysis
BALF for cell analysis was filtered through two-layer
sterile gauzes to remove mucus, and then cellular mate-
rials were sedimented by centrifugation (2500 rpm for
10 min at 4°C) and the supernatant was stored at −70°C
for cytokine analysis later. The pellet was re-suspended
in 1 ml phosphate buffered saline (PBS) for quantitative
cell count. The cell differentials of BALF were measured
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USA) for counting at least 200 cells. For analysis of
lymphocyte subpopulations 200 μl of cell suspensions
(2×106 cells) were incubated for 40 min at 4°C with
20 ml fluorescein isothiocyanate conjugated monoclonal
antibody (Becton Dickinson, San Jose, Ca, USA). Follow-
ing the incubation, 2 ml of cold PBS was added to the
pellet and washed at 2500 rpm for 10 min at 4°C.
Prepared BALF samples were examined by flow cytometry
(FACS Calibur, Becton Dickinson, San Jose, CA, USA).
Measurement of cytokines and biomarkers
The levels of cytokines in the supernatants of BALF
and blood were measured by the commercially available
enzyme-linked immunosorbent assay kits: interleukin
(IL)-1β, tumor necrosis factor (TNF)-α, IL-8, monocyte
chemoattractant protein (MCP)-1, IL-17, IL-10 and
transforming growth factor (TGF)-β1, and IL-1 receptor
antagonist (IL-1RA) (R&D Systems; Minneapolis, MN,
USA). The levels of biomarkers in the supernatants
of BALF and blood were determined by commercial
enzyme-linked immunosorbent assay kits according to
the manufacturer’s instructions: high mobility group box 1
(HMGB1, HMGB1 ELISA kit II; Shino-Test Corporation,
Tokyo); Krebs von den Lungen-6 (KL-6, Eisai, Tokyo,
Japan); receptor for advanced glycation end product
(RAGE, R&D Systems; Minneapolis, MN, USA); advanced
glycation end product (AGE, Cell Biolabs Inc., San Diego,
CA, USA); surfactant protein D (SPD, Biovendor, Modrice,
Czech Republic). The lower limits of these variables were
adapted as follows: IL-1β, 1 pg/ml; TNF-α, 4.4 pg/ml;
IL-8, 3.5 pg/ml; IL-17, 15 pg/ml; MCP-1, 5.0 pg/ml; IL-10,
3.9 pg/ml; TGF-β1, 4.61 pg/ml; IL-1RA, 6.3 pg/ml; SPD,
0.2 ng/ml; HMGB-1, 1 ng/ml; RAGE, 4.12 pg/ml and
KL-6, 201 U/ml.
Estimating number of Pneumocystis jirovecii fungus in the
lung
This technique was developed by Baughman and his
coworkers [11]. Briefly, the BALF specimens 400 ul
were spun onto glass slides, using a cytocentrifuge
(Cytospin; Shandon Southern Instruments, Sewickley,
PA, USA). The slides were air dried and then stained
with Riu’s stain (modified May-Giemsa stain). The
fungal load was semi-quantitatively measured by count-
ing the number of clusters of Pneumocystis jirovecii in
relation to 500 nucleated cells per slide.
Measurement of β-D-glucan
The concentration of β-D-glucan was measured by
Fungitell assay. It was performed according to the
protocol supplied by the manufacturer (Associates of
Cape Cod, MA, USA).Statistical analysis
Data were expressed as mean and SD or median and inter-
quartile range (IQR), where appropriate. Non-parametric
tests were used to analyze the variables because most of
them were not normally distributed. Comparisons of the
continuous variables between pure PJP and mixed PJP
patients were made using the Mann–Whitney U test. Com-
parisons of the variables in pure PJP patients who were
subdivided into two groups based on the variables including
oxygenation index, the use of ventilator or survivor status
were made using the Mann–Whitney U test. Multivariate
analysis was performed using stepwise logistic regression
analysis. Comparison for categorical variables between two
groups was examined using Chi-squared test and/or
Fisher exact, when appropriate. Significance was defined
as p <0.05. Statistical analysis was performed using SPSS
version 13 (SPSS, Chicago, IL, USA).
Results
Demographic characteristics, clinical features and cell
profiles in BALF
The demographic characteristics and clinical data of 65
non-AIDS patients. With PJP divided into two groups
are shown in Table 1. The oxygenation index, Acute
Physiology and Chronic Health Evaluation II scores,
intensive care unit (ICU) length of stay, the percentage
of ICU admission, use of ventilator and death showed
no significant differences between the pure PJP and
mixed PJP patients. The concurrent pulmonary infec-
tions included bacteria in four cases, aspergillus in one
case, CMV in nine cases, cryptococcus in two cases,
CMV and aspergillus in one case, and CMV and legion-
ella spp. in one case. The total cell count and cell
differentials, and lymphocyte subpopulations in BALF
are summarized in Table 2. There were no significant
differences in total cell count, cell differentials and
lymphocyte subpopulations between PJP patients with
and without concurrent pulmonary infection.
Comparisons of BALF and blood cytokines between pure
and mixed PJP patients
The blood IL-1β was not measured because of being
undetectable or very low levels based on our previous
experience. Comparisons of cytokines in BALF and blood
samples between pure PJP and mixed PJP patients are
given in Table 3. The levels of BALF anti-inflammatory
cytokines including IL-10, TGF-β1 and IL-1RA showed
no significant differences between the two groups.
The values of BALF IL-1β, TNF-α, IL-8 and the ratios
of IL-1β/IL-10, TNF-α/IL-10, IL-8/IL-10, IL-1β/TGF-β1,
TNF-α/TGF-β1, IL-8/TGF-β1 and IL-1β/IL-1RA were
significantly higher in mixed PJP than in pure PJP pa-
tients. The blood levels of IL-8 were significantly higher
in mixed PJP than those in pure PJP patients.
Table 1 Demographic and clinical characteristics of 65 patients with PJP
Pure PJP Mixed PJP P value
Gender(M/F) 25/22 9/9 0.818
Age, years 49.1 ± 16.0 50.6 ± 17.7 0.587
Underlying diseases
Hematological malignancy s/p chemotherapy 6 2
Allogeneic peripheral blood stem cell transplantation 3 2
Solid organ transplantation (kidney/heart/liver/pancreas/pancreas-kidney) 19/4/2/1/1 3/0/0/0/0
Connective tissue diseases with immunosuppresants 6 2
Glomerulonephritis with immunosuppresants 3 6
Prostate cancer with immunosuppresants 1 0
Breast cancer with immunosuppresants 0 1
Long-term steroid therapy 1 1
DM 0 1
PaO2/FiO2 before BAL 230.0(182.2;278.7) 245.4(158.3;322.9) 0.631
APACHE II scores 23.00(18.00;27.50) 23.50(20.25;26.50) 0.987
ICU admission, case number (%) 23(48.9) 12(66.7) 0.269
ICU length of stay (days) 19.0(7.3;24.0) 11.0(6.3;21.3) 0.456
Ventilator needed, case number (%) 24(51.1) 11(61.1) 0.667
Death, case number (%) 19(40.4) 10(55.6) 0.403
Data are expressed as case number and % in parenthesis or median IQR (25%;75%).
PJP = Pneumocystis jirovecii pneumonia; Mixed PJP = PJP with concurrent other pulmonary infections; PaO2 = arterial oxygen tension; FiO2 = fraction of inspired
oxygen; ICU = intensive care unit; BAL = bronchoalveolar lavage; APACHE = Acute Physiology and Chronic Health Evaluation.
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between pure and mixed PJP patients
No significant differences in the inflammatory biomarkers
levels in BALF or blood were observed when pure PJP
were compared with mixed PJP patients. The biomarkers
included KL-6, SPD, HMGB-1, RAGE and AGE. The
results are shown in Additional file 1: Table S1.Table 2 Comparisons of cell profile and lymphocyte subpopu
Pure PJP
(N =47)
Total cell count, 103/ml 46.00(21.24;95.16)
Macrophages, % 67.50(57.00;82.00)
Macrophage count, 103/ml 36.23(12.64;53.01)
Lymphocytes, % 10.25(3.00;29.63)
Lymphocyte count, 103/ml 3.39(1.18;17.04)
Neutrophils, % 10.50(4.88;20.88)
Neutrophil count, 103/ml 3.97(1.84;11.41)
CD4/CD8 ratio 22.30(8.50;37.40)
CD4+ cells, % 2.48(0.30;8.02)
CD4+ cells, 103/ml 31.80(15.80;59.70)
CD8+ cells, % 4.67(0.55;13.19)
CD8+ cells, 103/ml 0.67(0.31;1.20)
Data are expressed as median IQR (25%;75%).
BALF = Bronchoalveolar lavage fluid; PJP = Pneumocystis jirovecii pneumonia; Mixed
The comparison was made by Mann–Whitney U test.Comparisons of cytokines and cytokine ratios in BALF and
blood between concurrent bacterial and viral infection in
mixed PJP patients
We compared pro-inflammatory cytokines, anti-in-
flammatory cytokines and ratio of pro-inflammatory
cytokines/anti-inflammatory cytokines in both BALF
















PJP = PJP with concurrent other pulmonary infections.







IL-1β, pg/ml 2.13(1.66;2.91) 4.59(1.92;24.45) 0.024
TNF-α, pg/ml 10.10(8.83;13.08) 12.24(10.09;23.84) 0.026
IL-8, pg/ml 46.30(31.80;175.30) 298.85(110.98;434.63) 0.001
IL-17, pg/ml 15.00(15.00;15.00) 15.00(15.00;15.00) 0.883
MCP-1, pg/ml 1048.50(250.81;2842.70) 1140.25(459.46;2171.44) 0.649
IL-10, pg/ml 3.90(3.90;7.70) 3.90(3.90;3.90) 0.152
TGF-β1, pg/ml 49.60(42.10;60.30) 46.55(44.88;59.33) 0.899
IL-1RA, pg/ml 1177.95(609.10;2816.00) 1682.15(1174.78;4496.43) 0.257
IL-1β/IL-10 0.48(0.35;0.56) 1.18(0.29;5.22) 0.018
TNF-α/IL-10 2.33(1.26;2.64) 2.80(2.43;3.87) 0.011
IL-8/IL-10 10.21(4.69;29.44) 53.60(24.49;85.10) 0.001
IL-17/IL-10 3.85(3.17;3.85) 3.85(3.85;3.85) 0.698
MCP-1/ IL-10 214.87(55.52;362.63) 176.11(117.81;375.97) 0.567
IL-1β/TGF-β1 0.04(0.02;0.05) 0.11(0.03;0.42) 0.002
TNF-α/TGF-β1 0.19(0.11;0.25) 0.25(0.22;0.39) 0.004
IL-8/TGF-β1 0.76(0.28;2.22) 4.85(2.47;9.99) <0.001
IL-17/TGF-β1 0.31(0.26;0.37) 0.27(0.25;0.36) 0.570
MCP-1/TGF-β1 10.48(0.96;42.87) 18.54(10.85;39.91) 0.182
IL-1β/IL-1RA 0.00(0.00;0.00) 0.01(0.00.0.02) 0.048
TNF-α/IL-1RA 0.01(0.00;0.02) 0.01(0.00;0.02) 0.743
IL-8/IL-1RA 0.06(0.02;0.22) 0.11(0.05;0.76) 0.385
IL-17/IL-1RA 0.01(0.01;0.03) 0.01(0.00;0.02) 0.385
MCP-1/IL-1RA 0.99(0.23;1.52) 0.65(0.08;1.59) 0.905
Blood
TNF-α, pg/ml 12.00(9.00;17.10) 12.25(7.55;20.68) 0.829
IL-8, pg/ml 30.41(18.78;53.40) 71.80(32.90;136.33) 0.008
IL-17, pg/ml 15.00(15.00; 15.00) 15.00(15.00; 15.00) 0.832
MCP-1, pg/ml 1271.70(402.90;2229.20) 1928.80(525.95;3496.50) 0.285
IL-10, pg/ml 19.90(10.40;37.50) 33.90(9.88;62.53) 0.226
TGF-β1, pg/ml 458.20(245.89;7768.70) 5996.50(259.08;7819.45) 0.288
IL-1RA, pg/ml 884.00(354.68;2348.75) 2160.40(402.80;6116.50) 0.229
IL-8/IL-10 1.73(0.86;2.79) 2.38(0.92;6.05) 0.131
IL-8/TGF-β1 0.06(0.00;0.21) 0.01(0.00;0.30) 0.895
TNF-α/IL-10 0.56(0.35;1.12) 0.35(0.19;1.19) 0.284
TNF-α/TGF-β1 0.02(0.00;0.07) 0.00(0.00;0.07) 0.215
Data are expressed as median IQR (25%;75%).
BALF = Bronchoalveolar lavage fluid; PJP = Pneumocystis jirovecii pneumonia; Mixed PJP = PJP with concurrent other pulmonary infections; IL = Interleukin;
TGF-β1 = Transforming growth factor-β1; TNF-α = Tumor necrosis factor-α; MCP-1 =Monocyte chemoattractant protein-1; IL-1RA = IL-1 receptor antagonist.
The comparison was made by Mann–Whitney U test.
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groups. The results showed no significant differences in
the variables measured except for that BALF IL-1β/IL-1RA
ratio were significantly higher in bacterial infection group.
The results are shown in Additional file 2: Table S2.Comparisons of Pneumocystis jirovecii burden in the lung
The median number of Pneumocystis jirovecii in the lung
was 3 (IQR, 1;7) in pure PJP and 2.5 (IQR, 1;12) in
mixed PJP patients. There was no significant difference
between the two groups. The median levels of BALF β-
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(IQR, 148.30;442.40) and 260.60 (IQR, 134.40;623.40),
respectively. The median levels of serum β-D-glucan
in pure and mixed PJP patients were 213.00 (IQR,
19.90;784.50) and 215.65 (IQR, 75.45;7103.00), respect-
ively. The values of BALF and serum β-D-glucan were
not significantly different between the two groups.
Comparisons of cytokines and pro-inflammatory/anti-
inflammatory cytokine ratios between pure PJP patients
divided into groups by oxygenation index (PaO2/FiO2),
the use of ventilator and outcome
Comparisons between pure PJP patients with PaO2/FiO2 >
200 mmHg and PaO2/FiO2 ≤ 200 mmHg are shown in
Table 4. Compared to the patients with PaO2/FiO2 >
200 mmHg, those with PaO2/FiO2 ≤ 200 mmHg had
significantly higher BALF levels of IL-1RA, ratios of
IL-1β/TGF-β1, TNF-α/TGF-β1, IL-8/TGF-β1 and MCP-
1/TGF-β1, and had significantly higher blood levels of
TGF-β1 and ratios of IL-8/IL-10 and TNF-α/IL-10. The
ratios of IL-8/TGF-β1 and TNF-α/TGF-β1 in blood was
significantly lower in those with PaO2/FiO2 ≤ 200 mmHg.
However, after stepwise logistic regression analysis, none
of these variables was independent factor.
Compared with pure PJP patients without ventilator,
BALF levels of IL-8 were significantly higher and the
values of IL-10 were markedly lower in pure PJP patients
with ventilator. BALF ratios of IL-8/IL-10, IL-1β/TGF-
β1, TNF-α/TGF-β1, IL-8/TGF-β1, MCP-1/TGF-β1 and
MCP-1/IL-1RA, and blood levels of IL-8 and IL-10 and
were significantly higher in pure PJP patients with venti-
lator. The TNF-α/IL-10 ratio in blood was significantly
lower in those with ventilator (Table 5). However, after
stepwise logistic regression analysis, only BALF IL-8 was
the independent factor (p =0.023, 95% confident interval
[CI] =0.000-0.004).
Similar findings could be found in pure PJP patients
who were divided into subgroups by clinical outcome.
Compared with survivors, the non-survivors had signifi-
cantly higher BALF values of IL-8 and ratios of IL-8/IL-
10, IL-1β/TGF-β1, IL-8/TGF-β1, MCP-1/TGF-β1, IL-8/
IL-1RA and MCP-1/IL-1RA, and significantly higher
blood levels of IL-10 and IL-8. The blood level of
IL-1RA was significantly lower in non-survivors (Table 6).
However, after stepwise logistic regression analysis, only
BALF IL-8/TGF-β1 was the independent factor (p =0.018,
95% CI =0.022-0.186).
Comparisons of cytokines and pro-inflammatory/anti-
inflammatory cytokine ratios between mixed PJP patients
divided into groups by oxygenation index (PaO2/FiO2),
the use of ventilator and outcome
There were no significant differences in BALF and blood
levels of cytokines and pro-inflammatory/anti-inflammatorycytokine ratios between mixed PJP patients divided into
two groups by oxygenation index and the use of ventilator.
Compared with survived mixed PJP patients, BALF values
of IL-1β, TGF-β1, IL-1β/IL-1RA ratio were significantly
higher, and blood levels of TGF-β1 were markedly lower in
the deceased ones.
Discussion
Few studies discussed the difference in outcomes between
pure PJP and PJP with concurrent pulmonary infection in
non-AIDS immunocompromised patients. Most of the
papers were focused on the CMV co-infection in HIV
patients. However, the reported effect of concurrent
CMV pneumonia on the outcome of AIDS patients with
PJP was controversial. Some studies indicated that the
morbidity and mortality showed no significant differ-
ences between HIV-infected PJP patients with or without
concurrent CMV infection [12-15]. In contrast, AIDS
patients with PJP who had co-infection with CMV
pneumonia in other studies had higher mortality than
those with PJP only [16,17].
The role of concurrent CMV pneumonia in non-AIDS
patients with PJP has not yet been well investigated.
Miles et al. reported high mortality in non-HIV PJP
patients irrespective of whether they had CMV pneumonia
or not [15], but their case number was limited. Recently,
Kim and coworkers reported that concomitant pulmonary
CMV infection did not significantly affect the outcome
of PJP with respect to the morbidity and mortality in
non-HIV-infected patients with PJP [18]. To the best of
our knowledge, this is the first study to compare the
outcomes of non-AIDS PJP patients with or without
concurrent pulmonary infections, including CMV pneu-
monia. Our results showed no significant differences in
the morbidity and mortality between the two groups of
patients (Table 1). Because the studied cases of PJP with
concurrent pulmonary infection were limited and CMV
pneumonia appeared to be the most common concurrent
pulmonary infection, further studies with larger popula-
tions are needed to verify these issues.
Theoretically, exaggeration of pro-inflammatory or
anti-inflammatory cytokine response may result in
excessive inflammation leading to host tissue damage
and affect the outcome of the patients. The results of
our previous study indicated that as compared with
normal lung group, PJP patients had significantly
higher levels of pro-inflammatory cytokines and unvaried
anti-inflammatory cytokines, and some pro-inflammatory/
anti-inflammatory cytokine ratios were of value in asses-
sing the severity of PJP and in predicting the outcome of
the patients [10]. In the current study, the inflammatory
cellular responses, as reflected by total cell counts, cell
differentials and lymphocyte subpopulation in BALF,
between pure PJP and mixed PJP patients showed no
Table 4 Comparisons of pro-inflammatory and anti-inflammatory cytokines in BALF and blood between pure PJP




≤ 200 mmHg(N =9)
P value* P value#
BALF
IL-1β, pg/ml 2.24(1.85;2.86) 2.65(2.00;5.32) 0.414
TNF-α, pg/ml 10.09(7.82;12.44) 13.08(9.52;17.82) 0.154
IL-8, pg/ml 48.40(24.38;168.25) 175.30(35.00;342.90) 0.193
IL-17, pg/ml 15.00(15.00;15.00) 15.00(15.00;15.00) 0.645
MCP-1, pg/ml 1066.50(663.37;2593.31) 2453.16(715.00;4288.47) 0.254
IL-10, pg/ml 4.25(3.90;8.93) 3.90(3.90;8.12) 0.414
TGF-β1, pg/ml 53.40(45.45;128.30) 43.90(42.10;51.70) 0.150
IL-1RA, pg/ml 709.70(463.30;1730.20) 1835.20(929.33;2816.00) 0.045 0.144
IL-1β/IL-10 0.41(0.29;0.57) 0.54(0.40;1.36) 0.238
TNF-α/IL-10 2.33(1.19;2.63) 2.44(2.06;3.50) 0.179
IL-8/IL-10 8.83(3.67;32.04) 28.22(8.78;53.10) 0.166
IL-17/IL-10 3.85(2.84;3.85) 3.85(2.42;3.85) 0.547
MCP-1/ IL-10 220.15(110.95;334.84) 629.02(170.28;914.57) 0.131
IL-1β/TGF-β1 0.03(0.01;0.05) 0.06(0.03;0.13) 0.026 0.741
TNF-α/TGF-β1 0.16(0.03;0.22) 0.23(0.22;0.37) 0.003 0.421
IL-8/TGF-β1 0.63(0.16;1.84) 3.26(0.80;7.94) 0.032 0.787
IL-17/TGF-β1 0.29(0.27;0.33) 0.36(0.29;0.38) 0.121
MCP-1/TGF-β1 14.13(4.40;34.32) 58.27(13.32;107.14) 0.032 0.158
IL-1β/IL-1RA 0.00(0.00;0.01) 0.00(0.00;0.00) 0.210
TNF-α/IL-1RA 0.02(0.01;0.04) 0.01(0.00;0.01) 0.121
IL-8/IL-1RA 0.18(0.02;0.99) 0.07(0.02;0.12) 0.374
IL-17/IL-1RA 0.02(0.01;0.03) 0.01(0.01;0.02) 0.140
MCP-1/IL-1RA 0.99(0.24;4.05) 1.48(0.46;1.52) 0.750
Blood
TNF-α, pg/ml 14.50(10.60;17.50) 12.70(8.50;24.20) 0.640
IL-8, pg/ml 33.81(18.85;78.35) 41.20(21.60;90.55) 0.766
IL-17, pg/ml 15.00(15.00;15.00) 15.00(15.00;15.00) 0.643
MCP-1, pg/ml 1557.80(792.83;2655.05) 1382.60(318.75;2337.80) 0.512
IL-10, pg/ml 33.40(12.25;56.93) 20.80(9.65;32.95) 0.111
TGF-β1, pg/ml 255.15(168.10;3908.20) 3479.90(1020.85;10050.65) 0.014 0.892
IL-1RA, pg/ml 1087.90(297.10;2697.80) 701.80(286.90;2375.60) 0.938
IL-8/IL-10 1.22(0.59;1.76) 2.79(1.14;4.14) 0.020 0.903
IL-8/TGF-β1 0.12(0.04;0.48) 0.02(0.01;0.04) 0.020 0.787
TNF-α/IL-10 0.35(0.17;0.93) 0.72(0.43;1.34) 0.035 0.872
TNF-α/TGF-β1 0.07(0.02;0.24) 0.00(0.00;0.03) 0.012 0.233
Data are expressed as median IQR (25%;75%).
PaO2/FiO2 = arterial oxygen tension/fraction of inspired oxygen; BALF = Bronchoalveolar lavage fluid; PJP = Pneumocystis jirovecii pneumonia; IL = Interleukin;
TGF-β1 = Transforming growth factor-β1; TNF-α = Tumor necrosis factor-α; MCP-1 = Monocyte chemoattractant protein-1; IL-1RA = IL-1 receptor antagonist.
The comparison was made by Mann–Whitney U test.
P*: univariate analysis, P#: multivariate analysis.
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biomarkers in BALF and blood also did not demonstrate
significant differences between two groups of patients.An imbalance of pro-inflammatory/anti-inflammatory
cytokines was shown to be more exacerbated in mixed
PJP than in pure PJP patients (Table 3). However, our
Table 5 Comparisons of pro-inflammatory and anti-inflammatory cytokines in BALF and blood between pure PJP





P value* P value#
BALF
IL-1β, pg/ml 2.23(1.73;2.91) 2.10(1.53;3.46) 0.915
TNF-α, pg/ml 9.81(7.23;14.31) 10.30(9.09;12.84) 0.332
IL-8, pg/ml 35.63(22.28;70.59) 59.90(32.95;249.65) 0.023 0.043
IL-17, pg/ml 15.00(15.00;15.00) 15.00(15.00;15.00) 0.876
MCP-1, pg/ml 847.20(114.46;3158.55) 1048.50(326.90;2761.43) 0.565
IL-10, pg/ml 5.33(3.90;9.25) 3.90(3.90;5.50) 0.049 0.954
TGF-β1, pg/ml 53.40(42.10;707.20) 48.80(42.10;55.10) 0.203
IL-1RA, pg/ml 1323.10(566.70;3432.50) 1142.20(632.70;2303.10) 0.678
IL-1β/IL-10 0.39(0.26;0.55) 0.49(0.37;0.57) 0.119
TNF-α/IL-10 2.23(1.11;2.58) 2.51(2.06;2.71) 0.098
IL-8/IL-10 7.24(3.31;12.42) 15.36(8.26;48.67) 0.004 0.733
IL-17/IL-10 3.85(3.12;3.85) 3.85(2.84;3.85) 0.981
MCP-1/ IL-10 103.17(28.60;402.18) 262.10(74.72;397.89) 0.172
IL-1β/TGF-β1 0.03(0.00;0.05) 0.04(0.03;0.07) 0.018 0.545
TNF-α/TGF-β1 0.13(0.01;0.25) 0.21(0.18;0.26) 0.017 0.321
IL-8/TGF-β1 0.47(0.07;1.02) 1.35(0.73;5.61) <0.001 0.707
IL-17/TGF-β1 0.29(0.08;0.46) 0.31(0.27;0.36) 0.793
MCP-1/TGF-β1 5.13(0.50;36.72) 21.51(5.32;56.99) 0.023 0.369
IL-1β/IL-1RA 0.00(0.00;0.01) 0.00(0.00;0.00) 0.649
TNF-α/IL-1RA 0.01(0.00;0.02) 0.01(0.00;0.02) 0.756
IL-8/IL-1RA 0.03(0.01;0.08) 0.10(0.02;0.40) 0.126
IL-17/IL-1RA 0.02(0.00;0.03) 0.01(0.01;0.03) 0.943
MCP-1/IL-1RA 0.24(0.03;0.70) 1.47(0.28;1.85) 0.011 0.582
Blood
TNF-α, pg/ml 9.90(8.30;17.10) 12.45(10.20;17.15) 0.123
IL-8, pg/ml 22.30(14.23;40.75) 42.70(22.95;105.15) 0.004 0.969
IL-17, pg/ml 15.00(15.00;15.00) 15.00(15.00;15.00) 0.866
MCP-1, pg/ml 931.65(368.58;1719.33) 1382.60(459.80;2485.55) 0.354
IL-10, pg/ml 11.21(9.33;21.60) 32.90(13.35;47.25) 0.006 0.938
TGF-β1, pg/ml 260.35(225.00;11506.09) 557.50(269.85;5782.80) 0.898
IL-1RA, pg/ml 2114.30(693.50;3696.90) 701.80(286.90;2117.70) 0.169
IL-8/IL-10 1.83(0.80;2.61) 1.71(0.94;2.81) 0.966
IL-8/TGF-β1 0.04(0.00;0.15) 0.10(0.01;0.23) 0.159
TNF-α/IL-10 1.10(0.65;1.31) 0.45(0.25;0.74) 0.022 0.160
TNF-α/TGF-β1 0.00(0.00;1.80) 0.03(0.00;0.07) 0.540
Data are expressed as median IQR (25%;75%).
BALF = Bronchoalveolar lavage fluid; PJP = Pneumocystis jirovecii pneumonia; IL = Interleukin; TGF-β1 = Transforming growth factor-β1; TNF-α = Tumor necrosis
factor-α; MCP-1 = Monocyte chemoattractant protein-1; IL-1RA = IL-1 receptor antagonist.
The comparison was made by Mann–Whitney U test.
P*: univariate analysis, P#: multivariate analysis.
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morbidity and mortality between the two groups. It
remains unclear why there should be limited impactof concurrent pulmonary infection on the cell pro-
files of BALF and related immune responses involved
in PJP of non-AIDS immunocompromised patients.
Table 6 Comparisons of pro-inflammatory and anti-inflammatory cytokines in BALF and blood between survivors and





P value* P value#
BALF
IL-1β, pg/ml 2.21(1.68;3.51) 2.00(1.50;2.91) 0.948
TNF-α, pg/ml 10.07(7.98;14.05) 10.10(9.07;11.60) 0.761
IL-8, pg/ml 35.63(22.60;79.26) 114.80(36.70;375.60) 0.010 0.694
IL-17, pg/ml 15.00(15.00;15.00) 15.00(15.00;15.00) 0.751
MCP-1, pg/ml 736.49(218.78;2703.81) 1065.50(344.00;3069.70) 0.474
IL-10, pg/ml 4.61(3.90;8.89) 3.90(3.90;4.40) 0.079
TGF-β1, pg/ml 53.40(43.00;194.80) 48.80(41.20;54.13) 0.094
IL-1RA, pg/ml 1589.90(669.20;3178.55) 1077.40(512.40;1870.50) 0.254
IL-1β/IL-10 0.41(0.28;0.56) 0.49(0.36;0.57) 0.293
TNF-α/IL-10 2.33(1.15;2.63) 2.51(2.20;2.71) 0.193
IL-8/IL-10 8.26(3.66;13.75) 17.79(8.90;54.86) 0.002 0.735
IL-17/IL-10 3.85(3.48;3.85) 3.85(2.27;3.85) 0.451
MCP-1/ IL-10 112.85(39.67;334.84) 273.21(79.44;433.15) 0.146
IL-1β/TGF-β1 0.03(0.00;0.05) 0.04(0.03;0.06) 0.042 0.611
TNF-α/TGF-β1 0.15(0.01;0.26) 0.21(0.18;0.25) 0.091
IL-8/TGF-β1 0.51(0.13;1.03) 1.56(0.71;7.73) 0.001 0.018
IL-17/TGF-β1 0.28(0.23;0.41) 0.31(0.27;0.36) 0.505
MCP-1/TGF-β1 6.09(0.54;39.10) 21.57(5.49;58.27) 0.044 0.486
IL-1β/IL-1RA 0.00(0.00;0.00) 0.00(0.00;0.01) 0.451
TNF-α/IL-1RA 0.01(0.00;0.02) 0.01(0.00;0.02) 0.354
IL-8/IL-1RA 0.04(0.01;0.09) 0.12(0.03;0.53) 0.033 0.517
IL-17/IL-1RA 0.01(0.00;0.03) 0.01(0.01;0.03) 0.591
MCP-1/IL-1RA 0.28(0.18;1.14) 1.48(0.46;4.43) 0.012 0.329
Blood
TNF-α, pg/ml 11.10(8.56;18.20) 13.35(10.03;16.45) 0.335
IL-8, pg/ml 23.65(16.53;41.55) 47.10(26.80;136.60) 0.002 0.397
IL-17, pg/ml 15.00(15.00;15.00) 15.00(15.00;15.00) 0.781
MCP-1, pg/ml 1287.20(374.63;2124.20) 1014.60(529.10;2683.20) 0.537
IL-10, pg/ml 14.05(8.78;26.62) 33.00(11.60;47.10) 0.018 0.952
TGF-β1, pg/ml 1020.85(245.89;10269.20) 423.40(205.00;6450.50) 0.515
IL-1RA, pg/ml 1678.75(695.58;3536.63) 565.70(271.33;1594.93) 0.036
IL-8/IL-10 1.74(0.81;2.45) 1.73(1.25;4.05) 0.423
IL-8/TGF-β1 0.03(0.00;0.12) 0.12(0.02;0.24) 0.054
TNF-α/IL-10 0.93(0.43;1.23) 0.45(0.24;0.80) 0.083
TNF-α/TGF-β1 0.01(0.00;0.06) 0.05(0.00;0.09) 0.273
Data are expressed as median IQR (25%;75%).
BALF = Bronchoalveolar lavage fluid; PJP = Pneumocystis jirovecii pneumonia; IL = Interleukin; TGF-β1 = Transforming growth factor-β1; TNF-α = Tumor necrosis
factor-α; MCP-1 = Monocyte chemoattractant protein-1; IL-1RA = IL-1 receptor antagonist.
The comparison was made by Mann–Whitney U test.
P*:univariate analysis, P#:multivariate analysis.
Chou et al. BMC Pulmonary Medicine 2014, 14:182 Page 9 of 11
http://www.biomedcentral.com/1471-2466/14/182Further studies with larger populations are needed to
verify these issues.
T helper (Th) 17 cells, a subset of T helper cells,
appear to play an important role in fungal clearance anddefense [19,20]. Impaired IL-17 response was reported
to be associated with decreased clearance of Candida
and Aspergillus [21,22]. However, the role of IL-17
response in pneumocystis infection has not yet been well
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showed decreased levels of IL-17 in the lungs caused by
IL-23 deficiency or by neutralizing anti-IL-17 antibody
resulted in transient decrease (three weeks after infec-
tion) in clearance of pneumocystis organisms in mice
[23]. One previous study suggested that interferon-γ was
required to suppress Th17 differentiation, and Th17
response seemed to be ineffective to clear pneumocystis
infection in immunocompromised mice [24]. The only
IL-17 study in human subjects indicated that the levels
of alveolar lining fluid IL-17 showed no significant
difference between PJP infected patients and two PJP
free control groups of patients with or without immuno-
suppression [25]. However, all the three groups studied
included some patients with mixed pulmonary infec-
tions. The present study demonstrated that BALF levels
of IL-17 in pure PJP and mixed PJP patients were at the
lower limit except for one patient and showed no signifi-
cant difference. Furthermore, the BALF level of IL-17
and IL-23 did not differ between normal controls and
either pure PJP or mixed PJP patients (Additional file 3:
Table S3). This is in contrast with the previous study
showing the IL-23-IL-17 cytokine axis is involved in
murine pneumocystis carinii pneumonia [23]. The pos-
sible reason is that some inhibitors might depress or
neutralize the levels of IL-23 and IL-17. Another one is
that IL-23 and IL-17 might occur earlier in the disease
course and could not be detected later. The roles of
IL-23/IL-17 in PJP and mixed PJP with other respiratory
infection patients need further studies to explore.
It is of interest to see the effect of concurrent viral or
bacterial infection on the immune dysregulation of PJP,
and its clinical relevance in the non-AIDS immunocom-
promised patients with mixed PJP patients. The results
showed no significant differences in the variables measured
except for that BALF IL-1β/IL-1RA ratio were significantly
higher in bacterial infection subgroup (Additional file 2:
Table S2). Because the cases in each subgroup were limited
in this study, further studies with larger populations are
needed to verify the issues.
Our result showed values of BALF IL-8, IL-8/IL-10
ratio, IL-8/TGF-β1 ratio were significantly higher in
pure PJP patients with the neede of mechanical ventila-
tion and in deceased patients (Tables 5 and 6). After
stepwise logistic regression analysis, BALF level of IL-8 was
the independent factor for the need of mechanical ventila-
tion and BALF level of IL-8/TGF-β1 ratio was responsible
for the death in PJP of non-AIDS immunocompromised
patients. Taken together, BALF inflammatory cytokines or
inflammatory cytokines/anti-inflammatory cytokine ratios
alone may be not strong enough to serve as prognostic
factors. Some other factors including the entities of
immunosuppression in non-AIDS immunocomprom-
ised patients, associated co-morbidity and severity ofPJP at the diagnosis may be responsible for the need of
mechanical ventilation or death of the patients. Further
studies with larger populations are needed to verify
these issues.
Despite failing to demonstrate the effect of concur-
rent pulmonary infection on the outcome of non-AIDS
PJP patients, the present study confirmed that immune
dysregulation did occur in PJP of non-AIDS immuno-
compromised patients [10]. Accordingly, it is highly
suggested that steroid treatment may be indicated in
the treatment of PJP of non-AIDS immunocompromised
patients to damp the immune reconstruction syndrome or
immune restoration disease, which is characterized by a
condition of acute pulmonary compromise that is associ-
ated with return of immune function in immunocom-
promised patients with pulmonary infection who were
clinically stable prior to the return of immune function,
caused by pathogens of PJP [26,27].Conclusions
In summary, concurrent infection may cause more severe
immune dysregulation of PJP in non-AIDS immunocom-
promised patients, but has limited effect on the morbidity
and mortality of PJP patients. Because of limited number
of cases studied, further studies with larger populations
are needed to verify these issues.Additional files
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